Title
Combinatorial Therapeutic for Breast and Prostate Cancer Treatments
Present State of the Art
Hsp90 (heat shock proteins) are popular cancer drug targets due to their anti-apoptotic activities. Several classes of Hsp90 inhibitors are in clinical trial.
Problem of the Present Art
Hsp90 inhibitors are often successful in diminishing or deactivating the Hsp90 in the cancer cells. However, inhibition of Hsp90 is associated with the overexpression of Hsp70 and its anti-apoptotic activity.
Advantage of Invention
Researchers at GRU discovered that a certain capsaicinoid class of compounds are very effective inhibitors of Hsp70 with high selectivity. This present technology provides pharmaceutical compositions comprising of capsaicinoid based Hsp70 inhibitors and established Hsp90 inhibitors for the effective treatment of cancer.
GRU #2013-041